Antares Pharma Announces FDA Approval Of TLANDO™, an Oral Treatment for Testosterone Replacement Therapy
29 mars 2022 07h00 HE
|
Antares Pharma, Inc.
EWING, N.J., March 29, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration...
Antares Pharma Reports Fourth Quarter and Full-Year 2021 Financial and Operating Results
03 mars 2022 07h00 HE
|
Antares Pharma, Inc.
Full-Year 2021 Revenue Increased 23% Year-Over-Year to $184.0 Million Full-Year 2021 Net Income of $46.3 Million, or $0.26 Per Diluted Earnings Per Share Full-Year 2021 Adjusted EBITDA of $39.2...
Antares Pharma to Present at the Cowen 42nd Annual Healthcare Conference
28 févr. 2022 08h30 HE
|
Antares Pharma, Inc.
EWING, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief...
Antares Pharma To Report Fourth Quarter And Full-Year 2021 Financial And Operating Results
17 févr. 2022 08h30 HE
|
Antares Pharma, Inc.
EWING, N.J., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced it will release its fourth quarter and...
Antares Pharma Announces FDA Acceptance of NDA Resubmission for TLANDO®
03 févr. 2022 08h00 HE
|
Antares Pharma, Inc.
EWING, N.J., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration...
Antares Pharma Receives FDA Fast Track Designation for ATRS-1902 for Adrenal Crisis Rescue
18 janv. 2022 07h30 HE
|
Antares Pharma, Inc.
EWING, N.J., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration...
Antares Pharma Appoints Claude E. Richardson as Senior Vice President of Human Resources
12 janv. 2022 08h30 HE
|
Antares Pharma, Inc.
EWING, N.J., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, announced today the appointment of Claude E. Richardson as...
Antares Pharma Announces Positive Results From Phase I Study For ATRS-1902 For Adrenal Crisis Rescue
11 janv. 2022 07h30 HE
|
Antares Pharma, Inc.
EWING, N.J., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced positive results from a Phase I study for...
Antares Pharma Announces Divestiture of Otrexup®
15 déc. 2021 17h58 HE
|
Antares Pharma, Inc.
EWING, N.J., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced the divestiture of OTREXUP® (methotrexate)...
Antares Pharma to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
22 nov. 2021 08h00 HE
|
Antares Pharma, Inc.
EWING, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief...